Clinical Trial

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this research study is to see if people whose Acute myeloid leukemia (AML) is being successfully treated with azacitidine or decitabine in combination with venetoclax can discontinue this chemotherapy for some period of time after a year of treatment without increasing the likelihood that their AML will return.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-07-16; most recent amendment 2026-02-24.
Trial Details
NCT Number NCT06511882
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborators: AbbVie
Conditions Acute Myeloid Leukemia
Enrollment 37 participants
Start Date 2024-11-07
Primary Completion 2027-10 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-02-27